EpilepsyGTx
PrivateLast Round
Series A
Dec 10, 2025
Total Funding Raised
$43M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
EpilepsyGTx is a biotechnology company developing cutting-edge gene therapies to treat focal refractory epilepsy.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
EpilepsyGTx Comparables
Compare EpilepsyGTx with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Latus Bio | 84% | |
| Capsida Biotherapeutics | 81% | |
| Kriya Therapeutics | 80% |
EpilepsyGTx Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Dec 10, 2025 | ||||
| Seed | Jun 24, 2024 |
Key People
Founding team and executive leadership
EpilepsyGTx Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| XGEN Venture | Series A |
| British Business Bank | Series A |
| UCL Business | Seed |
| Albion Capital | Seed |
| Zcube | Seed |
| Health Technology Holding | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 28, 2026
Monthly visitors increased 41% MoM.
- Apr 29, 2026
Professor Dimitri Kullmann appointed as the new CSO.
Recent news
Latest coverage and updates
- is_developingSep 11, 2026
EpilepsyGTx is developing EPY201.
- is_developingSep 9, 2026
EpilepsyGTx is developing AAV gene therapy programme for epilepsy on Sep 9th '26.
- partners_withSep 9, 2026
EpilepsyGTx partnered with Viralgen on Sep 9th '26.
- hiresJul 22, 2026
EpilepsyGTx hired Teresa Nunes as Chief Medical Officer on Jul 22nd '26.
- is_developingJul 14, 2026
Epilepsygtx is developing targeted gene therapy approach for focal refractory epilepsy on Jul 14th '26.
EpilepsyGTx Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about EpilepsyGTx's valuation, stock price, and market status.
Is EpilepsyGTx a public or private company?
EpilepsyGTx is a private company.
What is the current stock price of EpilepsyGTx?
EpilepsyGTx is a private company with no public stock price. No recent secondary market data is available.
How much is EpilepsyGTx worth (valuation)?
Valuation information for EpilepsyGTx is not publicly available.
Can I buy EpilepsyGTx stock?
EpilepsyGTx shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was EpilepsyGTx's last funding round?
EpilepsyGTx's most recent funding round was Series A on December 10, 2025.
Who are the main investors in EpilepsyGTx?
Key investors in EpilepsyGTx include XGEN Venture, British Business Bank, UCL Business, Albion Capital.
Will EpilepsyGTx IPO soon?
No public IPO plans have been announced for EpilepsyGTx.
How can I track EpilepsyGTx secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor EpilepsyGTx's secondary market activity and sign up for updates.